LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "talquetamab" as a keyword



Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Sign Up to like & get
recommendations! Published in 2025 at "Blood Cancer Journal"

DOI: 10.1038/s41408-025-01386-7

Abstract: Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and January 2025 demonstrated significant efficacy in… read more here.

Keywords: multiple myeloma; talquetamab; real world; refractory multiple ... See more keywords

Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma

Sign Up to like & get
recommendations! Published in 2024 at "Current Medical Research and Opinion"

DOI: 10.1080/03007995.2024.2391553

Abstract: Abstract Objective Talquetamab is the first GPRC5D-targeting bispecific antibody approved for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). This matching-adjusted indirect comparison (MAIC) study was conducted to compare the effectiveness of talquetamab… read more here.

Keywords: dosing schedules; talquetamab; sel dex; refractory multiple ... See more keywords

BH17 A case of talquetamab-induced onychomadesis with associated palmoplantar keratoderma and desquamation

Sign Up to like & get
recommendations! Published in 2024 at "British Journal of Dermatology"

DOI: 10.1093/bjd/ljae090.164

Abstract: Herein we present the case of a 59-year-old woman who presented to our department with shedding of nails on all 10 fingers and toes, as well as desquamation of the skin on the palms of… read more here.

Keywords: keratoderma desquamation; talquetamab; onychomadesis; palmoplantar keratoderma ... See more keywords

Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-200593

Abstract: Background: G protein-coupled receptor class C group 5 member D (GPRC5D) has recently emerged as a promising immunotherapy target in Multiple Myeloma (MM) although its function remains unknown. Mono-allelic GPRC5D alterations are found in 15%… read more here.

Keywords: del; talquetamab; gprc5d; cell ... See more keywords

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Sign Up to like & get
recommendations! Published in 2022 at "Blood Advances"

DOI: 10.1182/bloodadvances.2022007625

Abstract: B-cell maturation antigen (BCMA) is selectively expressed as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of… read more here.

Keywords: sbcma levels; sbcma; bcma; talquetamab ... See more keywords